Ipca Laboratories Limited

BSE: 524494 NSE: IPCALAB
Ipca Laboratories Limited - pharma in Kandivali West, Maharashtra, India. FY 2026 financials & compliance.
CIN L24239MH1949PLC007837 Incorporated 19 October 1949 ROC Mumbai HQ Kandivali West, Maharashtra, India
Active Listed - NSE: IPCALAB · BSE: 524494 Public Limited Company pharma
Data last updated
Market Cap
₹50,667 Cr
IPCALAB · NSE
Share Price
₹1,970.80
-1.32% today
Revenue
₹9,646 Cr
FY 2025-26 · +4.8% YoY
EBITDA
₹1,878 Cr
Margin 19.5%
Net Profit
₹1,180 Cr
FY 2025-26 · +38.2% YoY
P/E (TTM)
36.3x
P/B 6.2x
ROE
15.9%
ROCE 19.0%
Debt / Equity
0.14
Interest cover 5.4x

About Ipca Laboratories Limited

Data last updated: 26 September 2026

Ipca Laboratories Limited is a public limited company based in Kandivali West, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 19 October 1949, the company has been in operation for over 77 years.

Registered with ROC Mumbai under CIN L24239MH1949PLC007837. Listed on BSE: 524494 and NSE: IPCALAB.

Capital: an authorised share capital of ₹57.6 Cr and a paid-up capital of ₹25.37 Cr. Formerly known as The Indian Pharmaceutical Combine Association Ltd. It is led by directors including Narendra Mairpady and Ajit Kumar Jain.

Last AGM: 11 August 2025. Financial statements filed for year ended 31 March 2025. Office: Kandivali West, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹9,646.33 Cr, a growth of 7.91% compared to the previous year. The net worth stands at ₹8,063.81 Cr (up 16.05% YoY). Total assets are valued at ₹10,431 Cr (up 5.92% YoY).

The company has a workforce of approximately 17,422 employees as per the latest available data. Its group structure includes 3 subsidiaries and 2 joint ventures.

The company is associated with 2 brands - Ipca Laboratories, Ipca Laboratories. As per MCA filings, the company has open charges of ₹2,303.63 Cr and satisfied charges of ₹2,406.67 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ipca.com.

Company Details of Ipca Laboratories Limited
CIN L24239MH1949PLC007837
Registration Number 007837
Incorporation Date 19 October 1949
ROC Mumbai
Listing Status Listed (BSE: 524494, NSE: IPCALAB)
Company Status Active
Date of Last AGM 11 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Ajit Kumar Jain Managing Director Pranay Premchand Godha Managing Director Premchand Gigalal Godha Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    ipca.com
  • Social Media
  • Registered Address
    48 Kandivli Industrial Estate, Kandivli (West), Kandivali West, Maharashtra, India – 400067
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers
Company report
Ipca Laboratories Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Ipca Laboratories Limited report

Financials, compliance, directors, charges, ownership and filings for Ipca Laboratories Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Ipca Laboratories Limited

Ipca Laboratories Limited operates two associated brands: Ipca Laboratories and Ipca Laboratories. These brands represent Ipca Laboratories Limited's diversified market presence and brand portfolio.

Brand Description Website
Ipca Laboratories
APIs and drug formulations are manufactured for therapeutic segments. ipca.com
Ipca Laboratories
Ipca Laboratories is engaged in pharmaceutical manufacturing and distribution. ipcalabs.com

Business Activity of Ipca Laboratories Limited

Ipca Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Ipca Laboratories Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Ipca Laboratories Limited

Ipca Laboratories Limited is audited by Natvarlal Vepari & Co for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
Natvarlal Vepari & Co Locked Locked Locked
Premium access

Complete auditor history for Ipca Laboratories Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Ipca Laboratories Limited

Ipca Laboratories Limited is currently managed by 8 directors, with 11 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Narendra Mairpady
Also directs: Kesar Enterprises Limited, Saatvik Green Energy Limited, Equippp Social Impact Technologies Limited and 5 more
Director 20 Oct 2022 3 Years 11 Months Current
Ajit Kumar Jain
Also directs: Ipca Foundation
Managing Director 21 Aug 2009 17 Years 1 Months Current
Kamal Kishore Seth
Also directs: Ipca Foundation, Gufic Biosciences Limited, Indo-Vietnamese Chamber Of Commerce And Industry
Director 29 Mar 2019 7 Years 5 Months Current
Pranay Premchand Godha
Also directs: Xgrow Traders Llp, Kaygee Laboratories Private Limited, Kaygee Investments Private Limited and 2 more
Managing Director 30 Jul 2009 17 Years 1 Months Current
Premchand Gigalal Godha
Also directs: Ipca Foundation, Xgrow Traders Llp, Kaygee Laboratories Private Limited and 1 more
Whole-Time Director 31 Jan 2012 14 Years 7 Months Current
Prashant Godha
Also directs: Ipca Foundation, Xgrow Traders Llp, Kaygee Laboratories Private Limited and 5 more
Director 28 Jul 2011 15 Years 1 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Ipca Laboratories Limited FY 2025-26 filings available

Ipca Laboratories Limited reported revenue of ₹9,646.33 Cr (up 7.91% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹9,646 Cr
+7.9% YoY
EBITDA
₹1,878 Cr
+23.2% YoY
Profit After Tax
₹1,180 Cr
+38.2% YoY
Net Worth
₹8,064 Cr
+16.1% YoY
Total Assets
₹10,431 Cr
+5.9% YoY
Total Debt
₹809 Cr
-40.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue9,6468,9407,7056,2445,8305,4204,619
Revenue growth+4.8%+13.1%+23.4%+17.7%+16.7%+4.2%+21.8%
EBITDA1,8781,5241,1489291,3131,548902
EBITDA margin+19.5%+17.1%+14.9%+14.9%+22.5%+28.6%+19.5%
Profit before tax1,5731,1318437451,1361,389739
Net profit1,1808545944548851,134597
Net profit margin+12.2%+9.6%+7.7%+7.3%+15.2%+20.9%+12.9%
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
Balance sheet
Total assets10,4319,8489,2537,4446,4215,0224,176
Net worth8,0646,9486,3325,8425,4924,7023,627
Total debt8091,3631,4381,481807265501
Cash & bank5653442971,853641365181
Net working capital4,0463,5863,4403,8732,6622,1311,676
Cash flow
Cash from operations1,1421,3219458068561,090570
Cash from investing(247)(870)(1,215)(725)(851)(521)(509)
Cash from financing(754)(283)(553)507427(306)(137)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,7882,3882,3922,5562,3092,2472,2452,355
Revenue growth (YoY)+20.8%+6.3%+6.6%+8.6%+10.3%+10.5%+9.4%+15.8%
Other income25.2693.7437.8427.8632.6625.8220.1126.26
EBITDA670438533487416224463441
EBITDA margin+24.0%+18.3%+22.3%+19.0%+18.0%+10.0%+20.6%+18.7%
Depreciation11110710810310010098.46100
Interest11.8820.2017.6219.6118.5121.5116.8122.56
Profit before tax572404446392331128368345
Tax14995.0581.9310896.0962.2290.5999.39
Net profit42330936428423465.78277245
EPS (₹)15.8411.7912.8611.149.192.679.789.05
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue7,3376,6786,1665,8155,4385,1394,338
Revenue growth+2.8%+6.8%+3.8%+16.8%+15.9%+5.9%+17.5%
EBITDA1,7521,2461,0809141,2411,517918
EBITDA margin+23.9%+18.7%+17.5%+15.7%+22.8%+29.5%+21.2%
Profit before tax1,5321,0008227501,0741,380785
Net profit1,1368206004888531,132642
Net profit margin+15.5%+12.3%+9.7%+8.4%+15.7%+22.0%+14.8%
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
Balance sheet
Total assets8,3437,8567,5517,3656,2965,0284,185
Net worth7,9796,8926,3495,8775,4764,7533,678
Total debt2959061,1521,440776236474
Cash & bank3631651131,706596307152
Net working capital2,4032,1042,1743,6492,5222,0371,615
Cash flow
Cash from operations1,3781,3748317628321,096561
Cash from investing(697)(739)(1,355)(710)(812)(560)(499)
Cash from financing(745)(428)(465)506426(307)(139)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,1191,8141,8451,9301,7471,6381,6631,811
Revenue growth (YoY)+21.3%+10.7%+11.0%+6.6%+11.6%+8.5%+10.3%+8.9%
Other income17.4229.8817.8221.9225.0221.4917.4117.00
Total expenses1,5421,4141,3681,4661,3401,5611,2521,409
EBITDA57840147746540777.05411402
EBITDA margin+27.3%+22.1%+25.9%+24.1%+23.3%+4.7%+24.7%+22.2%
Depreciation74.6170.3168.5766.8663.1365.1962.8162.65
Interest5.0410.489.5111.4612.0616.2010.1717.25
Profit before tax51535041740835717.15356339
Tax14287.5611410494.7182.2087.9695.09

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,7882,3882,3922,5562,3092,2472,2452,355
Revenue growth (YoY)+20.8%+6.3%+6.6%+8.6%+10.3%+10.5%+9.4%+15.8%
Other income25.2693.7437.8427.8632.6625.8220.1126.26
EBITDA670438533487416224463441
EBITDA margin+24.0%+18.3%+22.3%+19.0%+18.0%+10.0%+20.6%+18.7%
Depreciation11110710810310010098.46100
Interest11.8820.2017.6219.6118.5121.5116.8122.56
Profit before tax572404446392331128368345
Tax14995.0581.9310896.0962.2290.5999.39
Net profit42330936428423465.78277245
EPS (₹)15.8411.7912.8611.149.192.679.789.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue9,6468,9407,7056,2445,8305,4204,619
Revenue growth+4.8%+13.1%+23.4%+17.7%+16.7%+4.2%+21.8%
Other income19292.8019312666.5762.8467.00
Total expenses7,7697,4166,5575,3154,5173,8723,717
Employee cost2,1601,9841,7081,2881,1771,014921
EBITDA1,8781,5241,1489291,3131,548902
EBITDA margin+19.5%+17.1%+14.9%+14.9%+22.5%+28.6%+19.5%
Depreciation418398357262232209210
Interest79.0987.8414148.1911.2012.2719.77
Profit before tax1,5731,1318437451,1361,389739
Tax381344313253225240135
Net profit1,1808545944548851,134597
Net profit margin+12.2%+9.6%+7.7%+7.3%+15.2%+20.9%+12.9%
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.3725.3725.3725.3725.3725.3725.27
Reserves & surplus8,0386,9236,3075,8175,4674,6763,590
Shareholders' funds (net worth)8,0646,9486,3325,8425,4924,7023,627
Minority interest1,4601,4401,39573.3076.9214.5313.63
Secured loans7041,1561,210858555141324
Unsecured loans105206229623253124176
Total debt8091,3631,4381,481807265501
Total liabilities10,4319,8489,2537,4446,4215,0224,176
Assets
Gross block7,6926,9957,0214,3653,7593,2122,986
Net block4,6274,2674,5542,7512,4182,0722,059
Capital work in progress773622343140306235133
Investments844980862626989505310
Inventories2,7312,5602,4711,7431,8581,5951,323
Sundry debtors2,0141,8841,687989911812895
Cash & bank balances5653442971,853641365181
Loans & advances430415522280318272218
Total current assets5,7405,2044,9774,8663,7273,0432,617
Total current liabilities1,6941,6181,5389931,065913942
Net working capital4,0463,5863,4403,8732,6622,1311,676
Total assets10,4319,8489,2537,4446,4215,0224,176
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash9257561,579991559295371
Net cash from operating activities1,1421,3219458068561,090570
Net cash from investing activities(247)(870)(1,215)(725)(851)(521)(509)
Net cash from financing activities(754)(283)(553)507427(306)(137)
Net change in cash142169(823)588432264(75.53)
Closing cash5653442971,853641365181
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+7.9%+16.0%+23.4%+7.1%+7.6%+17.3%+23.3%
EBITDA growth+23.2%+32.8%+23.5%-29.2%-15.2%+71.5%+30.1%
PBT growth+39.0%+34.2%+13.1%-34.4%-18.2%+88.0%+35.2%
Net income growth+38.2%+43.8%+30.7%-48.7%-21.9%+90.0%+36.0%
Revenue CAGR (3Y)+15.6%+15.3%+12.4%+10.6%+15.9%+18.5%+13.5%
EBITDA CAGR (3Y)+26.4%+5.1%-9.5%+1.0%+23.7%+50.5%+26.2%
Profitability & leverage
Net income margin+12.4%+8.8%+6.9%+7.9%+15.6%+21.2%+13.1%
Return on capital employed+19.0%+17.1%+12.9%+11.6%+20.2%+30.6%+19.5%
Return on net worth+15.9%+13.6%+8.7%+8.7%+17.9%+27.6%+17.9%
Debt / equity0.140.210.240.200.110.090.14
Long-term debt / equity0.050.090.110.100.040.020.04
Interest cover5.427.8017.807.221.040.922.86
Efficiency & per share
Fixed asset turnover1.311.281.351.541.671.751.65
Inventory turnover3.653.553.663.473.383.713.88
Debtors turnover4.955.015.766.576.776.355.90
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
Dividend per share (₹)0.004.004.004.008.008.005.00
Book value per share (₹)317.85273.88249.59230.27216.47370.65286.15
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,1191,8141,8451,9301,7471,6381,6631,811
Revenue growth (YoY)+21.3%+10.7%+11.0%+6.6%+11.6%+8.5%+10.3%+8.9%
Other income17.4229.8817.8221.9225.0221.4917.4117.00
Total expenses1,5421,4141,3681,4661,3401,5611,2521,409
EBITDA57840147746540777.05411402
EBITDA margin+27.3%+22.1%+25.9%+24.1%+23.3%+4.7%+24.7%+22.2%
Depreciation74.6170.3168.5766.8663.1365.1962.8162.65
Interest5.0410.489.5111.4612.0616.2010.1717.25
Profit before tax51535041740835717.15356339
Tax14287.5611410494.7182.2087.9695.09
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue7,3376,6786,1665,8155,4385,1394,338
Revenue growth+2.8%+6.8%+3.8%+16.8%+15.9%+5.9%+17.5%
Other income94.6471.2911111152.9262.2464.69
Total expenses5,5855,4325,0874,9004,1973,6233,420
Employee cost1,6561,4791,3361,1931,102949871
EBITDA1,7521,2461,0809141,2411,517918
EBITDA margin+23.9%+18.7%+17.5%+15.7%+22.8%+29.5%+21.2%
Depreciation269252246229210188179
Interest45.4665.0612346.3410.4111.1318.84
Profit before tax1,5321,0008227501,0741,380785
Tax400349292245214239133
Net profit1,1368206004888531,132642
Net profit margin+15.5%+12.3%+9.7%+8.4%+15.7%+22.0%+14.8%
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.3725.3725.3725.3725.3725.3725.27
Reserves & surplus7,9546,8666,3235,8525,4504,7273,640
Shareholders' funds (net worth)7,9796,8926,3495,8775,4764,7533,678
Secured loans235726991858555114298
Unsecured loans60.06180161582222123176
Total debt2959061,1521,440776236474
Total liabilities8,3437,8567,5517,3656,2965,0284,185
Assets
Gross block5,0374,3884,1663,8893,3652,8992,689
Net block2,9692,5372,5242,4792,1531,8691,841
Capital work in progress45949017512329718284.19
Investments2,5362,6932,6541,0571,339868649
Inventories1,7081,5421,6771,6601,7801,5171,267
Sundry debtors1,2721,1661,027926824774839
Cash & bank balances3631651131,706596307152
Loans & advances304255282260306285215
Total current assets3,6473,1283,0994,5523,5052,8842,474
Total current liabilities1,2441,024925903983847859
Net working capital2,4032,1042,1743,6492,5222,0371,615
Total assets8,3437,8567,5517,3656,2965,0284,185
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash7225151,505946500272348
Net cash from operating activities1,3781,3748317628321,096561
Net cash from investing activities(697)(739)(1,355)(710)(812)(560)(499)
Net cash from financing activities(745)(428)(465)506426(307)(139)
Net change in cash(64.08)207(990)559446229(76.37)
Closing cash3631651131,706596307152
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.9%+8.3%+6.1%+6.9%+5.8%+18.5%+20.3%
EBITDA growth+40.7%+15.3%+18.1%-26.3%-18.2%+65.2%+31.9%
PBT growth+53.3%+21.6%+9.6%-30.1%-22.2%+75.8%+40.8%
Net income growth+38.5%+36.7%+22.9%-42.7%-24.7%+76.5%+43.0%
Revenue CAGR (3Y)+8.1%+7.1%+6.3%+10.3%+14.7%+17.2%+11.8%
EBITDA CAGR (3Y)+24.2%+0.1%-10.7%-0.1%+21.3%+50.5%+28.3%
Profitability & leverage
Net income margin+15.4%+9.7%+8.6%+8.7%+15.8%+22.2%+15.0%
Return on capital employed+19.5%+17.2%+14.1%+11.7%+19.2%+30.2%+20.6%
Return on net worth+15.2%+12.4%+9.8%+8.9%+16.8%+27.1%+19.2%
Debt / equity0.080.160.210.200.100.080.13
Long-term debt / equity0.040.080.100.090.040.010.03
Interest cover3.076.5514.716.761.010.842.55
Efficiency & per share
Fixed asset turnover1.561.561.531.601.741.841.71
Inventory turnover4.524.153.703.383.303.693.76
Debtors turnover6.026.096.316.646.806.375.94
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
Dividend per share (₹)6.004.004.004.004.008.005.00
Book value per share (₹)314.52271.64250.24231.66215.84374.67290.11
Want more history and ratios?
You're viewing the latest exchange-filed financials for Ipca Laboratories Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Ipca Laboratories Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 44.70%, foreign institutional investors hold 10.70%, domestic institutional investors hold 37.40%, retail and other public shareholders hold 7.20% of Ipca Laboratories Limited.

Promoters: 44.70%DII (Domestic Institutional): 37.40%FII (Foreign Institutional): 10.70%Retail & Others: 7.20%
Jun 2026
QUARTER
44.70% Promoters
37.40% DII (Domestic Institutional)
10.70% FII (Foreign Institutional)
7.20% Retail & Others
Promoter holding - history
Now 44.70% · Jun 2026High 44.70% · Sep 2025Low 44.70% · Sep 2025
43%43.8%44.5%45.3%46%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 44.70%Dec 2025: 44.70%Mar 2026: 44.70%Jun 2026: 44.70%44.70%44.70%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters44.70%44.70%44.70%44.70%
Public55.30%55.30%55.30%55.30%

Group Structure of Ipca Laboratories Limited

Ipca Laboratories Limited has 3 subsidiary companies, 2 joint ventures, and 3 associated companies. This group structure data is as of FY 2024. The corporate group structure reflects Ipca Laboratories Limited's business expansion strategy and organizational complexity.

3
Subsidiary companies
2
Joint ventures
3
Associated companies
Key Subsidiaries
Company Name CIN Shares Held
Unichem Laboratories Limited L99999MH1962PLC012451 -
Trophic Wellness Private Limited U24100MH2010PTC206526 -
Ipca Foundation U85300MH2021NPL360586 -

Showing major subsidiaries. Total: 3.

Charges & Borrowings of Ipca Laboratories Limited

Open charges
₹2,303.63 Cr
Satisfied charges
₹2,406.67 Cr
Breakdown by lending institutions
Idbi Trusteeship Services Limited₹1,510.00 Cr
Hdfc Bank Limited₹691.22 Cr
Kotak Mahindra Bank Limited₹29.70 Cr
Canara Bank₹28.22 Cr
Icici Banking Corporation Ltd.₹20.00 Cr
Others₹24.49 Cr
Latest charge details
DateLenderAmountStatus
29 Aug 2023 Hdfc Bank Limited ₹300 Cr Open
07 Oct 2022 Hdfc Bank Limited ₹391.22 Cr Open
25 Mar 2022 Others ₹1.9 Cr Open
11 Mar 2022 Others ₹10 Lakh Open
03 May 2013 Idbi Trusteeship Services Limited ₹790 Cr Open

Total charge records: 108 View all charges

Employees and EPFO Compliance at Ipca Laboratories Limited

Ipca Laboratories Limited has a workforce of 17,422 employees as of Feb 28, 2025.

Employee count
17,422
Active EPFO establishments
17
Employee growth
-6.99%
Premium access

Employee and EPFO history for Ipca Laboratories Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Ipca Laboratories Limited

Premium access

GST registrations and filing compliance for Ipca Laboratories Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Ipca Laboratories Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Ipca Laboratories Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Ipca Laboratories Limited

Premium access

MSME payment history for Ipca Laboratories Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Ipca Laboratories Limited

Premium access

Corporate group structure for Ipca Laboratories Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Ipca Laboratories Limited

Premium access

MCA filings and documents for Ipca Laboratories Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Ipca Laboratories Limited

Charges
11 Feb 2026
A charge registered on 24 Jan 2025 via Charge ID 101041701 with Citi Bank N.A. was fully satisfied on 11 Feb 2026.
Charges
09 Jan 2026
A charge registered on 08 Aug 2023 via Charge ID 100768745 with The Hongkong And Shanghai Banking Corporation Limited was fully satisfied on 09 Jan 2026.
Charges
07 Jan 2026
A charge registered on 02 Aug 2022 via Charge ID 100633351 with Jp Morgan Chase Bank, N.A. was fully satisfied on 07 Jan 2026.
Activity
11 Aug 2025
Ipca Laboratories Limited last Annual general meeting of members was held on 11 Aug 2025 as per latest MCA records.
Activity
31 Mar 2025
Ipca Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Charges
24 Jan 2025
A charge with Citi Bank N.A. amounted to Rs. 166.60 Cr with Charge ID 101041701 was registered on 24 Jan 2025.

Recent News on Ipca Laboratories Limited

Pharma stocks flout market slump on US tariffs exemption
03 Apr 2025 · Thehindubusinessline
Stocks that will see action today: 13 February, 2025
13 Feb 2025 · Thehindubusinessline

Frequently Asked Questions about Ipca Laboratories Limited

Ipca Laboratories Limited is an active public limited company in the pharma sector based in Kandivali West, Maharashtra, India. It was incorporated on 19 October 1949 (77+ years old) and is registered under CIN L24239MH1949PLC007837. Listed on BSE: 524494 and NSE: IPCALAB. The company has 17,422 employees.

Ipca Laboratories Limited reported revenue of ₹9,646.33 Cr for FY 2025-26 (up 7.91% YoY) based on consolidated financials.

The current directors of Ipca Laboratories Limited are:

The primary industry of Ipca Laboratories Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Ipca Laboratories Limited is listed on both BSE (code: 524494) and NSE (symbol: IPCALAB).

Ipca Laboratories Limited can be reached at the registered office: 48 Kandivli Industrial Estate, Kandivli West, Kandivali West, Maharashtra, India – 400067, or through the website ipca.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available